Last reviewed · How we verify

Dosing Interruption of Natalizumab

Berkovich, Regina MD, PhD Inc. · FDA-approved active Small molecule Quality 6/100

Dosing Interruption of Natalizumab is a Small molecule drug developed by Berkovich, Regina MD, PhD Inc.. It is currently FDA-approved. Also known as: Dosing Interruption of Tysabri.

At a glance

Generic nameDosing Interruption of Natalizumab
Also known asDosing Interruption of Tysabri
SponsorBerkovich, Regina MD, PhD Inc.
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dosing Interruption of Natalizumab

What is Dosing Interruption of Natalizumab?

Dosing Interruption of Natalizumab is a Small molecule drug developed by Berkovich, Regina MD, PhD Inc..

Who makes Dosing Interruption of Natalizumab?

Dosing Interruption of Natalizumab is developed and marketed by Berkovich, Regina MD, PhD Inc. (see full Berkovich, Regina MD, PhD Inc. pipeline at /company/berkovich-regina-md-phd-inc).

Is Dosing Interruption of Natalizumab also known as anything else?

Dosing Interruption of Natalizumab is also known as Dosing Interruption of Tysabri.

What development phase is Dosing Interruption of Natalizumab in?

Dosing Interruption of Natalizumab is FDA-approved (marketed).

Related